INFLUENZAVACCINE BASED ON RECOMINANT MODIFIED VACCINIAVIRUS ANKARA (MVA)

• 1. 基于重组修饰的安卡拉痘苗(MVA)病毒的通用流感疫苗 [P] . 中国专利： CN102740880A . 2012-10-17
• 2. 重组修饰的痘苗病毒安卡拉(MVA)丝状病毒疫苗 [P] . 中国专利： CN106999565B . 2021.03.05
• 3. RECOMBINANT VECTORS BASED ON THE MODIFIED VACCINIAVIRUS ANKARA (MVA) AS VACCINES AGAINST LEISHMANIASE [P] . AT547530T . 2012-03-15

  机译： 基于改良疫苗安卡拉（MVA）的重组载体对利什曼病的疫苗接种

• 4. second strain of the modified Vacciniavirus Ankara (MVA) [P] . DK1263936T3 . 2006-02-13

  机译： 修饰的痘苗病毒安卡拉（MVA）的第二株

• 5. Intergeniske regioner som innskuddsseter i genomet til vacciniavirus ankara(MVA) [P] . NO20045480A . 2004-12-16

  机译： 基因间区域作为牛痘病毒安卡拉（MVA）基因组中的插入位点

• 1. Construction of Recombinant Modified Vaccinia Ankara (MVA) Expressing Hepatitis B Virus Surface Antigen [J] . 高等学校化学研究（英文版） . 2006,第002期
• 2. Chemically modified carbon-based electrodes for the determination of paracetamol in drugs and biological samples [J] . Wafaa Boumya, Nawal Taoufik, Mounia Achak, 药物分析学报（英文） . 2021,第002期
• 3. Ag-modified hydrogen titanate nanowire arrays for stable lithium metal anode in a carbonate-based electrolyte [J] . Zhipeng Wen, Dongzheng Wu, Hang Li, 能源化学：英文版 . 2021,第003期
• 4. Beschluss des Fachausschusses Virusdesinfektion der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten e.V. (DVV) vom 1. September 2010 zum Austausch von Vacciniavirus, Stamm Elstree gegen das Modifizierte Vacciniavirus Ankara (MVA) als Testvirus im Rahmen der Viruzidieprüfung entsprechend der DVV/RKI-Leitlinie in der Fassung vom 01.08.2008 [J] . Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz . 2010,第10期
• 5. Bewertung von Kultivierungsstrategien fur die Produktion des modifizierten Vacciniavirus Ankara (MVA) in Hochzelldichte [J] . D. Vazquez, Y. Genzel, I. Jordan Chemie-Ingenieur-Technik: Verfahrenstechnik Technische Chemie Apparatewesen Biotechnologie . 2014,第9期
• 6. Immunization of rhesus monkeys with a recombinant of modified vacciniavirus Ankara expressing a truncated envelope glycoprotein of dengue type 2virus induced resistance to dengue type 2 virus challenge [J] . Men R., Wyatt L., Tokimatsu I., Vaccine . 2000,第27期
• 7. Viral sensitizer technology improves yield of modified vaccinia ankara from available cell substrates [C] . Facrice Le Boeuf Vaccine technology IV . 2012
• 8. Effects of Modified Vaccinia Virus Ankara Expressing Mesothelin and the Poxvirus Immunoregulatory A35R gene in the Treatment of Murine Pancreatic Cancer [D] . Freistaedter, Andrew 2012
• 9. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine [O] . Xiaoying Shen, Rahul Basu, Sheetal Sawant, 2017
• 10. Introduction of the Six Major Genomic Deletions of Modified Vaccinia Virus Ankara (MVA) into the Parental Vaccinia Virus Is Not Sufficient To Reproduce an MVA-Like Phenotype in Cell Culture and in Mice▿ [O] . Meisinger-Henschel, Christine, Späth, Michaela, Lukassen, Susanne, 2010
• 11. Evaluation of the Efficacy of Modified Vaccinia Ankara (MVA)/IMVAMUNE (registered trademark) Against Aerosolized Rabbitpox Virus in a Rabbit Model [R] . Garza, N. L., Hatkin, J. M., Livingston, V., 2009

• 1. Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study [J] . Nour Ibrahim ,Hassan El Said ,Ali Choukair . 世界临床病例杂志 . 2022,第1期
• 2. Evaluating Rock Mass Properties of Vipingo Coral Limestone Quarry Based on a Modified Geological Strength Index (GSI) and State of Karstification [J] . Joan Atieno Onyango ,Takashi Sasaoka ,Hideki Shimada . 地质学期刊(英文) . 2022,第1期
• 3. 共表达PRRSV修饰的GP5与M蛋白的重组改良型痘苗病毒安卡拉株的构建及免疫效力 [C] . . 中国畜牧兽医学会动物传染病学分会第三届猪病防控学术研讨会 . 2008
• 4. JEV多表位基因重组痘苗病毒安卡拉株(rMVA-mep)及其免疫效果评价 [A] . 王凤娟 . 2011